Sage transitioned to the MiniMed™ 670G system so she could worry less about her diabetes management and focus more on her Olympic training. Hear her story.Φ
Diabetes doesn't have to stop Julie from shredding the slopes. With the MiniMed™ 670G system, she can spend her time telemark skiing while worrying less about her diabetes!Φ
Mason, a 9-year-old boy, and his mother Karen, share their incredible type 1 diabetes journey and talk about how the MiniMed™ 670G system has changed their lives for the better.Φ
Ambar has type 1 diabetes. But it doesn’t define her. Hear her share her story about the MiniMed™ 670G system.Φ
For more information about our solutions that are currently available, complete the form or call today at 1-888-350-5440 (M-F 9AM-6PM CST).
Φ The patient testimonial above relates an account of an individual’s response to treatment. The account is genuine, typical and documented. However, this patient’s response does not provide any indication, guide, warranty or guarantee as to the response other people may have to the treatment. The response other individuals have to the treatment could be different. Responses to the treatment can and do vary. Not every response is the same. Please talk to your doctor about your condition and the risks and benefits of these technologies.
Sage and Nicky were compensated for spending the day with us and allowing us to photograph them. Their thoughts and opinions are their own. Individual results may vary.
Julie, Addie, Ambar, Cara, Cory, Karen, Whitney, Phyllis, Chris, Nikhita and Jason were all compensated previously for spending the day with us and allowing us to photograph/videotape them. These blogs were not included in that compensation. Their thoughts and opinions are their own. Individual results may vary.
Gina and Amanda are employees of Medtronic. Their thoughts and opinions are their own.
Important Safety Information: MiniMed™ 670G System
The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.
WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library.
MiniMed is a registered trademark and SmartGuard is a trademark of Medtronic, MiniMed Inc.
940M20576-011 19APR2019 © 2019 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.